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SUMMARY - The aim of the study was to analyze the usefulness and side effects of treatment with 
interferon beta 1B (Betaferon) in patients with the relapsing-remitting form of multiple sclerosis 
(RRMS). The study included 32 RRMS patients that had completed two-year therapy with interfe-
ron beta 1B or were still receiving this therapy. Every six months, patients were clinically evaluated 
and scored by the Expanded Disability Status Scale (EDSS). Two-year therapy was completed by 11 
(34.3%) of 32 RRMS patients. Relapse was verified in 4 (36.36%) patients. The mean EDSS score 
was 2.45±1.03 at the beginning of therapy and 2.54±O.98 after two-year therapy; the difference was 
not statistically significant. In 2 (6.25%) patients on therapy for 18 months there was no relapse, 
and the mean EDSS was 1.75±0.35 (both at therapy introduction and at 18 months). Five (15.62%) 
patients were on therapy for one year. The mean EDSS was 1.6±1.08 at the beginning of therapy and 
l.S±0.70 at one year. One patient experienced relapse. Two patients were on therapy for six months. 
They had no relapses with the same EDSS at six months as at therapy introduction (2.0). At the 
beginning of2008, another 12 patients started therapy with interferon beta lB. In conclusion, our 
experience with two-year interferon beta-1B therapy for RRMS is favorable, with a relatively low 
rate of relapses (36.36%) and without significant worsening on EDSS. The medication side effects 
were mild and transient. 
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Introduction Patients and Methods 
Multiple sclerosis (MS) was described and defined 
by Charcot in 1868, however, therapy has remained 
a great challenge ever since. Research into the causes 
and treatments of MS has expanded our knowledge 
of the disease, promising better management of MS 
patients in the future l The aim of the study was to 
analyze our results on the usefulness and side effects 
of interferon beta 1B (Betaferon) treatment of patients 
with the relapsing-remitting form ofMS (RRMS). 
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The study included 32 RRMS patients treated at 
University Department of Neurology, Tuzla Universi-
ty Clinical Center, that had completed two-year ther-
apy with interferon beta IB or were still receiving this 
therapy. All patients were admitted to the Depart-
ment at the beginning of therapy or during relapse. 
Every six months, patients were clinically evaluated 
and scored by the Expanded Disability Status Scale 
(EDSS). Standard statistical tests, mean and t-test 
were used. Statistical significance was set at P<O.OS. 
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Results 
The mean patient age was 30.78±8.99 years and 
the mean disease duration before therapy introduction 
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Five (15,62%) patiert , were on therapy fcr me ye'lf, 
Their mean EDSS was 1. 6.1. 08 at the beginning md 
1.5.0,70 at me year oftheraf'i' 0,.., patimt experi-
elXed rdapse, Two patimts were m therapy for six 
mmths, They had no rdapse" ",j their mem EDSS 
was the same (1,0) at tn" beginning md after six 
mmths of ther'f'y. At the begirnirt; ofl008, another 
11 patimts st'lfted therapy with interferm beh dB, 
The most ccmmon side elfect, wer e elevatim of 
body temperature, redness at the s ~ e of needle inser-
tim md muscl e pain (Fig, 3), 
Discussion 
Althoogh disease rdapse was verified in 3ff1o of 
patimts during two-ye'lf therapy with irter fer m beh 
1 B, tn"re was no statisticillly significart wcr sening m 
EDSS, Previoos studies have ref'Xted simU'lf result", 
Scme mthcrs fooM prctmged theraf'i with irt erfer-
on ~ (lFN-~) to frequ ertly lead to the devdCftIlmt of 
arti-IFN -~ bindirt; mt t> odies (BAbs), which is asso-
ciated w~h reduced dinicill efficacy of theraw-', We 
could not malyze tn" levd ofBAbs md the risk of a 
new rdapse in IFN-~ treated patiert s, 
The medicatim side elfects were tempcr'lfy md 






Fig, ), Expanded D"abi£ty 
Statu , Seal, (EDSS) bifor, 
and after b,to/iron therapy, 
Fig, J, Diotributwn if 
medicatwn sid, 'ff'ct" 
Act> Cl n CrNt. Vol. 48, No.4, 2009 
MiIjana Vidovic et al. 
body temperature, redness at the site of needle inser-
tion and muscle pain. In our series of IFN-j) treated 
patients, there was no case of elevated aminotrans-
ferase levels and severe hepatic injury? 
Conclusion 
Our experiences with two-year interferon beta-1B 
treatment for RRMS at Tuzla Department of Neurol-
ogy are favorable. Our patients had a relatively low rate 
of relapses, without significant worsening of EDSS. 
The medication side effects were temporary and mild. 
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Saietak 
BETAFERON U LIJECENJU MULTIPLE SKLEROZE 
M. Vidovii, 0. Sinanovii,A. Burina,j. HudiiiA. Sehanovii 
Cilj studije bio je analizirati korist i nuspojave lijecenja bolesnika s relapsno-remisijskim oblikom multiple skleroze 
(RRMS) interferonom beta IB (Betaferon). U studiju je bilo ukljuceno 32 bolesnika s RRMS koji su zavrsili dvogodisnju 
terapiju interferonom beta 1B iii su ovu terapiju jos uvijek primali. Svakih sest mjeseci provodila se kliniCka procjena bo-
lesnika i procjena prema ljestvici EDSS (Expanded Disability Status Scale). DvogodiSnju terapiju zavrSilo je 20 (62,50%) od 
32 bolesnika. Recidiv je dokazan u 8 (40,00%) bolesnika. Prosjeean rezultat na ljestvici EDSS bio je 2,17±0,99 na pocetku 
lijecenja i 2,40±1,15 nakon dvije godine terapije; razlika nije bila statisticki znaeajna. Jedanaestoro (34,37%) bolesnika bilo 
je na terapiji jednu godinu. Kod njih je prosjeean rezultat na ljestvici EDSS bio 1,54±0,65 na pocetku terapije i 1.45±0,65 
nakon jedne godine lijecenja. Recidiv je zabiljeien u dvoje (18,18%) bolesnika, dok je jedan bolesnik prekinuo lijecenje 
nakon sest mjeseci. NaSa iskustva s dvogodisnjim lijecenjem RRMS interferonom beta 1B su povoljna. Bolesnici su imali 
relativno mali broj recidiva (40%) bez znatnijeg pogorSanja na ljestvici EDSS. Nuspojave lijeka bile su prolazne i blage 
naravi. 
Kljucne rijeci: Multipla skleroza - terapiJa liJekovima; Interftron-beta - terapiJska primjena; Interferon-beta - Stetni uCinci 
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